FRANKFURT (Reuters) - German healthcare group Fresenius (FREG_p.DE: Quote, Profile, Research) has secured a $2.4 billion credit facility to finance its $3.7 billion acquisition of U.S. company APP Pharmaceuticals APPX.O, it said on Wednesday.

A company spokesman said the loan, managed by Deutsche Bank, Credit Suisse and JP Morgan, comprised of a $650 million revolving facility, a $900 million loan at 2.875 percent over Libor and a $850 million loan at 3.5 percent over Libor.

Fresenius has said it plans to finance the purchase with a mix of debt and equity aimed at minimising the impact on Fresenius's credit ratings, with the largest portion through debt.

(Reporting by Patricia Gugau, writing by Mantik Kusjanto; Editing by David Cowell)